For instance, TEXT and SOFT trials have shown that exemestane plus ovarian suppression provides a greater absolute benefit to premenopausal women with HR-positive, HER2-negative early breast cancer who have low PR and/or high Ki-67, although each marker by itself has limited predictive value for adjuvant endocrine selection [41]. Here, MKI67 is linked to breast cancer.